bsm-41414M [Primary Antibody]
SARS-CoV-2 Nucleocapsid Protein Monoclonal Antibody (7E1B)
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]

Host: Mouse

Target Protein: SARS-CoV-2 N protein

Clonality: Monoclonal

Isotype: IgG2b

Swiss Prot: P0DTC9

Purification: Purified by Protein G.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C for 12 months.


Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.

Size: 100ul

Concentration: Lot Dependant

Applications: WB(1:300-5000)

Cross Reactive Species: Virus

For research use only. Not intended for diagnostic or therapeutic use.

  • Larry L. Luchsinger. et al. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients. J Clin Microbiol. 2020 Nov;58(12):e02005-2Read more>>
  • Daniel K. Jin. et al. Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and Reopening. Plos One. 2021 Apr;16(4):e0250319Read more>>
  • Nesbitt, Daniel J.. et al. Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats. Bmc Infect Dis. 2021 Dec;21(1):1-9Read more>>
  • Lassaunire, Ria. et al. Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2. Npj Vaccines. 2021 Dec;6(1):1-13Read more>>
  • Anders Frische. et al. Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay. PLOS ONE. 2022 Jul;17(7):e0272298Read more>>

Lane 1: SARS-CoV-2 N protein(Cat# bs-41408P) at 50ng; Lane 2: SARS-CoV-2 N protein(Cat# bs-41408P) at 25ng; Lane 3: SARS-CoV-2 N protein(Cat# bs-41408P) at 5ng; Lane 4: SARS-CoV-2 N protein(Cat# bs-41408P) at 2ng ; Lane 5: SARS-CoV-2 N protein(Cat# bs-41408P) at 1ng;Lane 6: SARS-CoV-2 N protein(Cat# bs-41408P) at 0.5ng probed with SARS-CoV-2 N protein monoclonal Antibody, Unconjugated (bsm-41414M) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.